FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
This article was originally published in The Gray Sheet
Executive Summary
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis
You may also be interested in...
CMS Tech Council Implementation Requires Industry Involvement – Grissom
CMS' Council for Technology & Innovation will offer an unprecedented opportunity for device firms to help bring transparency to the agency - as long as industry assists in the panel's creation, Boston Scientific VP-Government Affairs Tom Grissom said at AdvaMed's annual meeting March 4
CMS Tech Council Implementation Requires Industry Involvement – Grissom
CMS' Council for Technology & Innovation will offer an unprecedented opportunity for device firms to help bring transparency to the agency - as long as industry assists in the panel's creation, Boston Scientific VP-Government Affairs Tom Grissom said at AdvaMed's annual meeting March 4
Scully Calls Reimbursement Squeeze-Play On Prices; CMS/FDA MoU Imminent
CMS is curbing device prices by setting reimbursement levels for new technology at slightly lower rates than the prices charged by manufacturers, according to Administrator Tom Scully